{"url":"https://lda.senate.gov/api/v1/filings/7d764e35-34ca-4f96-99c8-e975b6fcaed8/","filing_uuid":"7d764e35-34ca-4f96-99c8-e975b6fcaed8","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2018,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/7d764e35-34ca-4f96-99c8-e975b6fcaed8/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Hannah Lambiotte Smith","dt_posted":"2018-04-20T15:58:53.337000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"300 New Jersey Avenue NW","registrant_address_2":"Suite 1025","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":401103077,"url":"https://lda.senate.gov/api/v1/registrants/401103077/","house_registrant_id":null,"name":"LINCOLN POLICY GROUP","description":"Government affairs consulting","address_1":"300 New Jersey Avenue NW","address_2":"Suite 1025","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"HANNAH LAMBIOTTE SMITH","contact_telephone":"+1 479-601-1106","dt_updated":"2026-01-30T15:44:14.095336-05:00"},"client":{"id":197840,"url":"https://lda.senate.gov/api/v1/clients/197840/","client_id":330,"name":"OPIOID TREATMENT PROGRAM (OTP) CONSORTIUM","general_description":"Consortium of drug-treatment facilities.","client_government_entity":false,"client_self_select":null,"state":"TX","state_display":"Texas","country":"US","country_display":"United States of America","ppb_state":"TX","ppb_state_display":"Texas","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-06-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Medicaid reform, health reform, funding and coverage for opioid use disorder treatment.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66086,"prefix":null,"prefix_display":null,"first_name":"DAN","nickname":null,"middle_name":null,"last_name":"ELLING","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66085,"prefix":null,"prefix_display":null,"first_name":"COLIN","nickname":null,"middle_name":null,"last_name":"ROSKEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66536,"prefix":null,"prefix_display":null,"first_name":"REGINA","nickname":null,"middle_name":"MARIA","last_name":"SHERICK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}